$DOC

Healthpeak Properties Reports Third Quarter 2026 Results and Increases Full Year 2026 Earnings Guidance

HEALTHPEAK PROPERTIES, INC. (DOC) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Healthpeak Properties Reports Third Quarter 2026 Results and Increases Full Year 2026 Earnings Guidance DENVER, November 2, 2026 - Healthpeak Properties, Inc. (NYSE: DOC) ("Healthpeak"), a leading owner, operator, and developer of real estate for healthcare discovery

Original reporting
Published Nov 2, 2026, 9:10 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 2, 2026, 9:15 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$DOC
Bullish
high confidence
Mentioned
$DOC
Relevance
7/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$DOCBullishHigh
01

Why it matters

The earnings beat and guidance increase provide fresh data that can shift valuation models.

02

Market read

The new guidance may attract buying interest in the REIT sector and influence related healthcare property stocks.

03

What to watch

Potential headwinds from rising interest rates could offset earnings upside.

Relevance 7/10Novelty 8/10Timing: after-hours release

Background

Healthpeak Properties is a leading owner and operator of healthcare real estate, filing its Q3 2026 results via an 8‑K.

Company-level read

Ticker impact

$DOCBullishHigh confidence
Context

Healthpeak Properties reported Q3 2026 results and raised full-year 2026 earnings guidance.

Expected impact

likely upward pressure as investors price in higher earnings expectations

Evidence & confidence

The company posted a modest Q3 profit and increased its full-year earnings guidance, which typically supports the stock price.

Market effects

Boosts sentiment for healthcare real estate REITs.

Supports US REIT sector performance.

Limited to investors focused on US real estate and healthcare infrastructure.

Counterpoint

If the guidance raise is already priced in, the stock may face a short‑term pullback.

Key entities

  • Healthpeak Properties

    Healthcare real estate REIT that issued the earnings and guidance update.

Related articles

$CCIMed

Better High-Yield Dividend Stock: Crown Castle vs. Healthpeak

Crown Castle (CCI) and Healthpeak Properties (PEAK) both raised 2026 outlooks in Q2. CCI yields 5.4% with a 93% AFFO payout ratio for 2026, while PEAK yields 6.7% with a 78% ratio. CCI trades at 16x forward AFFO, PEAK at 12x. Both have cut dividends previously. CCI's Q2 AFFO rose to $1.13/share, with full-year outlook at $4.53-$4.65.

$DOCMedAI 8/10

Healthpeak (DOC) Turns Portfolio Sales Into Fatter 2026 Guidance

Healthpeak Properties (DOC) raised its 2026 guidance, citing strong performance in outpatient medical and lab leasing, and significant growth at its senior housing operator, Janus Living (JAN). The company reported $0.46 FFO per share, flat year-over-year, and used asset sales to reduce debt and fund buybacks. Lab segment NOI declined, and leverage remains at 4.7x EBITDAre.

$DOCMed

Healthpeak Properties Q2 Earnings Call Highlights

Healthpeak Properties (NYSE:DOC) highlighted Q2 results and updates on capital recycling and leasing. It recapitalized a Brookfield outpatient portfolio, retaining 51% interest and raising $1B cash, and noted a 5.9% trailing cash cap rate. Lab occupancy rose to 78.5%. Net debt/adj. EBITDA was 4.7x with $4.1B liquidity; it repaid $900M debt and repurchased $100M shares.

$DOCMed

Is Wall Street Bullish or Bearish on Healthpeak Properties Stock?

Healthpeak Properties (DOC) is a U.S. healthcare REIT with a $14.9B market cap. The stock rose 31.8% over the past year and nearly 41% in 2026. After Q2 2026 results on Aug. 4, revenue was $771.6M and adjusted FFO was $0.46, both above estimates. Full-year FFO guidance is $1.73 to $1.77. Analysts rate DOC a “Moderate Buy,” with Barclays holding a $23 target.